NASDAQ:ABUS
Arbutus Biopharma Corporation Stock News
$2.58
-0.0200 (-0.769%)
At Close: Mar 28, 2024
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
02:30pm, Wednesday, 08'th Jun 2022
Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the declin
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
02:05am, Wednesday, 08'th Jun 2022
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ET
Arbutus to Participate in June Investor Conferences
07:30am, Thursday, 02'nd Jun 2022
WARMINSTER, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus Biopharma Corp (ABUS) CEO William Collier on Q1 2022 Results - Earnings Call Transcript
02:05pm, Thursday, 05'th May 2022
Arbutus Biopharma Corp, Inc. (NASDAQ:ABUS ) Q1 2022 Earnings Conference Call May 5, 2022 8:45 AM ET Company Participants Lisa Caperelli - VP, IR William Collier - President, CEO & Director Michael Sof
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
10:33am, Thursday, 05'th May 2022
Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update
07:30am, Thursday, 21'st Apr 2022
WARMINSTER, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove
Arbutus price target raised at H.C. Wainwright on upcoming data readouts
12:23pm, Monday, 14'th Mar 2022 Seeking Alpha
Arbutus Biopharma (ABUS) is trading ~4% higher in the pre-market Monday after H.C
Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
04:33pm, Monday, 07'th Mar 2022
Arbutus expects to have data readouts from three phase 2 triple combination studies using AB-729 for Hepatitis B in the 2nd half of 2022.
Arbutus Biopharma (ABUS) Q4 2021 Earnings Call Transcript
10:30pm, Thursday, 03'rd Mar 2022 The Motley Fool
ABUS earnings call for the period ending December 31, 2021.
Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call Transcript
07:31pm, Thursday, 03'rd Mar 2022 Seeking AlphaArbutus Biopharma Corporation 2021 Q4 - Results - Earnings Call Presentation
06:47pm, Thursday, 03'rd Mar 2022 Seeking AlphaArbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call Transcript
02:31pm, Thursday, 03'rd Mar 2022
Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call Transcript
Arbutus Biopharma GAAP EPS of -$0.83 beats by $0.03, revenue of $11M beats by $0.35M (NASDAQ:ABUS)
12:33pm, Thursday, 03'rd Mar 2022 Seeking Alpha
Arbutus Biopharma press release (ABUS): FY GAAP EPS of -$0.83 beats by $0.03.Revenue of $11M (+59.2% Y/Y) beats by $0.35M.Shares -0.3% PM.CEO comment: “We formed strategic and…
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
12:20pm, Thursday, 03'rd Mar 2022
Arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma Q4 2021 Earnings Preview
04:52pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
Arbutus Biopharma (NASDAQ:ABUS) is scheduled to announce Q4 results on Thursday, Mar. 3, before market open.Consensus EPS estimate is -$0.20 and consensus revenue estimate is $2.87M.